Mechanisms by which interleukin-6 regulates prostate-specific antigen gene expression in prostate LNCaP carcinoma cells

Journal of Andrology

Volumn 32, Issue 4, 2011, Pages 383-393

  Tsui, Ke Hung ^a   Lin, Yu Fen ^b   Chen, Yu His ^b   Chang, Phei Lang ^a   Juang, Horng Heng ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

17aag; Hsp90; Il 6; Maz; Psa; Stat3

Indexed keywords

ALVESPIMYCIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; INTERLEUKIN 6; MYC PROTEIN; PROSTATE SPECIFIC ANTIGEN; STAT3 PROTEIN; ZINC FINGER PROTEIN; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; BENZOQUINONE DERIVATIVE; C MYC ASSOCIATED ZINC FINGER PROTEIN; C-MYC-ASSOCIATED ZINC FINGER PROTEIN; DNA BINDING PROTEIN; MACROCYCLIC LACTAM; TANESPIMYCIN; TRANSCRIPTION FACTOR;

ARTICLE; CELL PROLIFERATION; CELL STRAIN LNCAP; GENE DELETION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CARCINOMA; SIGNAL TRANSDUCTION; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

BENZOQUINONES; CELL LINE, TUMOR; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INTERLEUKIN-6; LACTAMS, MACROCYCLIC; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS;

EID: 80052627657     PISSN: 01963635     EISSN: 19394640     Source Type: Journal    
DOI: 10.2164/jandrol.109.009878     Document Type: Article

References (48)

1. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol. 1999;161:182-187.
2. Ahmedin J, Rebecca S, Elizabeth W, Taylor M, Jiaquan X, Carol S, Michael JT. Cancer statistics. CA Cancer J Clin. 2006;56:106-130.
3. Balk SP, Ka YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol. 2003;21:383-391.
4. Chen T, Wang LH, Farrar WL. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res. 2000;60:2132-2135.
5. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, Shuai K. Specific inhibition of Stat3 signal transduction by PIAS3. Science. 1997;278:1803-1805.
6. Cross M, Liu B, Tan J-A, French FS, Garey M, Shuai K. Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene. 2001;20:3880-3887.
7. Culig Z, Steiner H, Bartsch G, Hobisch A. Interleukin-6 regulation of prostate cancer cells growth. J Cell Biochem. 2005;95:497-505.
8. Cullinan SB, Whitesell L. Heat shock protein 90: a unique chemotherapeutic target. Semin Oncol. 2006;33:457-465.
9. DeMiguel F, Lee SO, Lio W, Xiao X, Pflug BR, Nelson JB, Gao AC. Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice. Prostate. 2002;52:123-129.
10. Dhir R, Ni Z, Lou W, DeMiguel F, Grandis JR, Gao AC. Stat3 activation in prostatic carcinomas. Prostate. 2002;51:241-246.
11. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate. 1999;41:127-133.
12. Duan HO, Simpson-Haidaris PJ. Functional analysis of interleukin 6 response elememts (IL-6REs) on the human c-fibrinogen promoter. J Biol Chem. 2003;273:41270-41281.
13. Edwards J, Bartlett JMS. The androgen receptor and signaltransduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways. BJU Int. 2005;95:1327-1335.
14. Ehret GB, Reichenbach P, Schindler U, Horvath CM, Fritz S, Nabholz M, Bucher P. DNA binding specificity of different STAT proteins. J Biol Chem. 2001;276:6675-6688.
15. George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res. 2005;11:1815-1820.
16. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol. 2001;159:2159-2165.
17. Godoy-Tundidor S, Cavarretta ITR, Fuchs D, Fiechtl M, Steiner H, Friedbichler K, Bartsch G, Hobisch A, Culig Z. Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rvl cells through the signaling pathway of p38 mitogene-activated protein kinase and phosphatidylinositol 3 kinase. Prostate. 2005;64:209-216.
18. Haura EB, Turkson J, Jove R. Mechanisms of disease: insight into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol. 2005;2:315-323.
19. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 1998;58:4640-4645.
20. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z. Prostate cancer cells (LNCaP) generated after long-term interleukin-6 treatment express interleukin-6 and acquire an interleukin-6-partially resistant phenotype. Clin Cancer Res. 2001;7:2941-2948.
21. Horinaga M, Okita H, Nakashima J, Kanao K, Sakamoto M, Murai M. Clinical and pathologic significance of activation of signal transducer and activator of transcription 3 in prostate cancer. Urology. 2005;66:671-675.
22. Hsieh ML, Juang HH. Cell growth effects of triiodothyronine and expression of thyroid hormone receptor in prostate carcinoma cells. J Androl. 2005;26:422-428.
23. Jia L, Choong CS, Ricciardelli C, Kim J, Tilley WD, Coetzee GA. Androgen receptor signaling: mechanism of interleukin-6 inhibition. Cancer Res. 2004;64:2619-2626.
24. Junicho A, Matsuda T, Yamamoto T, Kishi H, Korkmaz K, Saatcioglu F, Fuse H, Muraguchi A. Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells. Biochem Biophy Res Comm. 2000;278:9-13.
25. Kotaja N, Aittomaki S, Silvennoinen O, Palvimo JJ, Janne OA. ARIP3 (androgen receptor-interacting protein 3) and other PIAS (protein inhibitor of activated STAT) proteins differ in their ability to modulate steroid receptor-dependent transcriptional activation. Mol Endocrinol. 2000;14:1986-2000.
26. Lee HL, Pienta KJ, Kim WJ, Cooper CR. The effect of boneassociated growth factors and cytokines on the growth of prostate cancer cells derived from soft tissue versus bone metastases in vitro. Int J Oncol. 2003;22:921-926.
27. Lin DL, Whitney MC, Yao Z, Keller ET. Interleukin-6 induces androgen responsiveness in prostate cancer cells through upregulation of androgen receptor expression. Clin Cancer Res. 2001;7:1773-1781.
28. Malinowska K, Neuwirt H, Cavarretta IT, Bektic J, Steiner H, Dietrich H, Moser PL, Fuchs D, Hobisch A, Culig R. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocrine-Related Cancer. 2009;16:155-169.
29. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingstron S, Karras J, Pow-Sang J, Jove R. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002;62:6659-6666.
30. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res. 2000;6:2702-2706.
31. Palmer J, Hertzog PJ, Hammacher A. Differential expression and effects of gp130 cytokines and receptors in prostate cancer cells. Int J Biochem Cell Biol. 2004;36:2258-2269.
32. Pang ST, Hsieh WC, Chuang CK, Chao CH, Weng WH, Juang HH. Thioredoxin-interacting protein: an oxidative stress-related gene is upregulated by glucose in human prostate carcinoma cells. Mol Cell Endocrinol. 2009;42:205-214.
33. Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D, Corey E. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer. 2003;97:1211-1216.
34. Ramanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG, Lan J, Potter DM, Lvy SP, Ramalingam S, Brufsky AM, Wong MKK, Tutchko S, Egorin MJ. Phase I pharmacokinetic- pharmacodynamic study of 17-(allylamino)-17-demethoxy-geldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancer. Clin Cancer Res. 2005;11:3385-3391.
35. Ray AA. SAF binding site in the promoter region of human gammafibrinogen gene functions as an IL-6 response element. J Immunol. 2000;165:3411-3417.
36. Ray A, Yu G-Y, Ray BK. Cytokine-responsive induction of SAF-1 activity is mediated by a mitogene-activated protein kinase signaling pathway. Mol Cell Biol. 2002;22:1027-1035.
37. Ripley BJM, Isenberg DA, Latchman DS. Elevated levels of the 90 kDa heat shock protein (hsp90) in SLE correlate with levels of IL-6 and autoantibodies to hsp90. J Autoimmun. 2001;7:341-346.
38. Royuela M, Ricote M, Parsons MS, Garcia-Tunon I, Paniagua R, De Miguel MP. Immunohistochemical analysis of the IL-6 family of cytokines and their receptor in benign, hyperplasic and malignant human prostate. J Pathol. 2004;202:41-49.
39. Sanford DC, Dewille JW. C/EBPd is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells. Prostate. 2004;63:143-154.
40. Sato N, Yamamoto T, Sekine Y, Yumioka T, Junicho A, Fuse H, Matsuda T. Involvement of heat-shock protein 90 in the interleukin-6-mediated signaling pathway through STAT3. Biochem Biophy Res Comm. 2003;300:847-852.
41. Solit DB, Scher H, Rosen N. Hsp90 as a therapeutic target in prostate cancer. Semin Oncol. 2003;30:709-716.
42. Tsui KH, Chang PL, Lin HT, Juang HH. Down-regualtion of the prostate specific antigen promoter by p53 in human prostate cancer cells. J Urol. 2004a;172:2035-2039.
43. Tsui KH, Feng TH, Hsieh WC, Chang PL, Juang HH. Expression of Interleukin-6 is downregulated by 17-(allylamino)-17-demethoxygeldanamycin in human prostatic carcinoma cells. Acta Pharmacol Sin. 2008a;29:1334-1341.
44. Tsui KH, Feng TH, Lin CM, Chang PL, Juang HH. Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells. J Androl. 2008b;29:661-668.
45. Tsui KH, Hsieh WC, Lin MH, Chang PL, Juang HH. Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2. Prostate. 2008c;68:610-619.
46. Tsui KH, Wu L, Chang PL, Hsieh ML, Juang HH. Identifying the combination of the transcriptional regulatory sequences on prostate specific antigen and human glandular kallikrein genes. J Urol. 2004b;172:2029-2034.
47. Wang L, Banerjee S. Differential PIAS3 expression in human malignancy. Oncol Reports. 2004;11:1319-1324.
48. Yamamoto T, Sato N, Sekine Y, Yumioka T, Imoto S, Junicho A, Fuse H, Matsuda T. Molecular interactions between STAT3 and protein inhibitor of activated STAT3, and androgen receptor. Biochem Biophy Res Comm. 2003;306:610-615.